BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 19804837)

  • 1. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease.
    Iclozan C; Yu Y; Liu C; Liang Y; Yi T; Anasetti C; Yu XZ
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):170-8. PubMed ID: 19804837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease.
    Yi T; Zhao D; Lin CL; Zhang C; Chen Y; Todorov I; LeBon T; Kandeel F; Forman S; Zeng D
    Blood; 2008 Sep; 112(5):2101-10. PubMed ID: 18596226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Inflammatory T Helper Cells
    Buchele V; Abendroth B; Büttner-Herold M; Vogler T; Rothamer J; Ghimire S; Ullrich E; Holler E; Neurath MF; Hildner K
    Front Immunol; 2018; 9():1138. PubMed ID: 29910804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease.
    Yi T; Chen Y; Wang L; Du G; Huang D; Zhao D; Johnston H; Young J; Todorov I; Umetsu DT; Chen L; Iwakura Y; Kandeel F; Forman S; Zeng D
    Blood; 2009 Oct; 114(14):3101-12. PubMed ID: 19602708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical role of host gammadelta T cells in experimental acute graft-versus-host disease.
    Maeda Y; Reddy P; Lowler KP; Liu C; Bishop DK; Ferrara JL
    Blood; 2005 Jul; 106(2):749-55. PubMed ID: 15797996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin attenuates acute graft-versus-host disease severity via in vivo regulations on Th1, Th17 and regulatory T cells.
    Park MJ; Moon SJ; Lee SH; Yang EJ; Min JK; Cho SG; Yang CW; Park SH; Kim HY; Cho ML
    PLoS One; 2013; 8(6):e67171. PubMed ID: 23840617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GRIM19 ameliorates acute graft-versus-host disease (GVHD) by modulating Th17 and Treg cell balance through down-regulation of STAT3 and NF-AT activation.
    Park MJ; Lee SH; Lee SH; Kim EK; Lee EJ; Moon YM; La Cho M
    J Transl Med; 2016 Jul; 14(1):206. PubMed ID: 27391226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The identification and characteristics of IL-22-producing T cells in acute graft-versus-host disease following allogeneic bone marrow transplantation.
    Zhao K; Zhao D; Huang D; Song X; Chen C; Pan B; Wu Q; Cao J; Yao Y; Zeng L; Xu K
    Immunobiology; 2013 Dec; 218(12):1505-13. PubMed ID: 23816304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deviated balance between Th1 and Th17 cells exacerbates acute graft-versus-host disease in mice.
    Pan B; Zhang Y; Sun Y; Cheng H; Wu Y; Song G; Chen W; Zeng L; Xu K
    Cytokine; 2014 Aug; 68(2):69-75. PubMed ID: 24845795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects.
    Jung U; Foley JE; Erdmann AA; Eckhaus MA; Fowler DH
    Blood; 2003 Nov; 102(9):3439-46. PubMed ID: 12855580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells.
    Wang MG; Szebeni J; Pearson DA; Szot GL; Sykes M
    Transplantation; 1995 Sep; 60(5):481-90. PubMed ID: 7676498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
    Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
    Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFN-γ receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation.
    Sun K; Hsiao HH; Li M; Ames E; Bouchlaka M; Welniak LA; Hagino T; Jagdeo J; Pai CC; Chen M; Blazar BR; Abedi M; Murphy WJ
    J Immunol; 2012 Aug; 189(4):2033-42. PubMed ID: 22778394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An absence of donor TH17 differentiation ameliorates dermal tissue damage].
    Cheng H; Song GL; Pan B; Tian J; Yan ZL; Chen W; Xu KL; Li ZY; Zeng LY
    Zhonghua Yi Xue Za Zhi; 2011 Jul; 91(26):1843-6. PubMed ID: 22093788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptively transferred gamma delta T cells indirectly regulate murine graft-versus-host reactivity following donor leukocyte infusion therapy in mice.
    Drobyski WR; Vodanovic-Jankovic S; Klein J
    J Immunol; 2000 Aug; 165(3):1634-40. PubMed ID: 10903774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations.
    Carlson MJ; West ML; Coghill JM; Panoskaltsis-Mortari A; Blazar BR; Serody JS
    Blood; 2009 Feb; 113(6):1365-74. PubMed ID: 18957685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice.
    Yu Y; Wang D; Liu C; Kaosaard K; Semple K; Anasetti C; Yu XZ
    Blood; 2011 Nov; 118(18):5011-20. PubMed ID: 21856864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.
    Krenger W; Snyder KM; Byon JC; Falzarano G; Ferrara JL
    J Immunol; 1995 Jul; 155(2):585-93. PubMed ID: 7608537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IL-12/23 p40 antibody attenuates experimental chronic graft-versus-host disease via suppression of IFN-γ/IL-17-producing cells.
    Okamoto S; Fujiwara H; Nishimori H; Matsuoka K; Fujii N; Kondo E; Tanaka T; Yoshimura A; Tanimoto M; Maeda Y
    J Immunol; 2015 Feb; 194(3):1357-63. PubMed ID: 25527789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
    Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.